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Original repOrt
The objective of this study was to determine the prevalence of 
ABO and Rh phenotypes in the general Pakistan population. 
This information could be used to help reduce the rate of 
alloimmunization in patients with blood disorders, such as 
thalassemia major, who require frequent blood transfusions. 
A total of 242 patients with blood disorders requiring frequent 
blood transfusions were enrolled in the study. ABO and Rh typing 
was performed on samples from these patients using tube and gel 
methods. Of these 242 patients, 146 (60.4%) were male and 96 
(39.6%) were female. The prevalence of ABO and D phenotypes 
was as follows: group O, D+ (38.8%), group O, D– (2.5%), group B, 
D+ (32.2%), group A, D+ (17.4%), group A, D– (1.7%), and group 
AB, D+ (7.4%). Of the 242 patients, 232 (95.8%) were D+ and 10 
(4.2%) were D–. The most prevalent Rh antigen was found to be 
e (97%), followed by D (95%), C (89.6%), c (62.8%), and lastly, 
E (22.6%). The prevalence of Rh phenotypes was: R1R1 (37.7%), 
R1r (33.4%), R1R2 (19.4%), R2r (5.2%), and rr (4.3 %). All of the 
D– patients were rr. In our study, the highest prevalence of ABO 
phenotypes was group O and the most prevalent Rh antigen was e. 
Rh phenotyping, along with antibody screening and identification 
should be performed prior to transfusion of patients requiring 
multiple transfusions to reduce and possibly prevent the rate of 
alloimmunization. Immunohematology 2016;32:170–173.
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Among the blood group systems discovered to date, the 
ABO and Rh systems are the most clinically significant in 
the field of transfusion medicine.1–3 The ABO system was 
identified by Karl Landsteiner in 1901, and the Rh system 
was delineated in 1940 by Landsteiner and Weiner.3,4 The 
ABO blood group system is critical because it is the only blood 
group system in which antibodies are constantly, predictably, 
and naturally present in the serum of people who lack the 
antigen.2 Currently, more than 50 Rh antigens have been 
discovered in the Rh system, 5 of which are associated with 
commonly made clinically significant antibodies, namely, D, 
C, E, c, and e.3,5,6
Both systems are important because of the immuno-
genicity of their antigens and the potency of their antibodies; 
the diverse genetic polymorphism within the Rh system is 
particularly immunogenic, because Rh antigens have been 
implicated in hemolytic disease of the newborn and delayed 
hemolytic transfusion reactions.3,6 Previous studies that 
focused on patients with thalassemia of predominantly 
Asian descent emphasized that transfusion of phenotypically 
matched blood for the four Rh antigens, compared with blood 
phenotypically matched for the standard ABO and D antigens, 
proves to be effective in preventing alloimmunization.7,8 
In Pakistan, thalassemia major constitutes the major bulk 
of red blood cell (RBC) transfusion-dependent disorders where 
alloimmunization is frequently observed—with Rh antigens 
being implicated as the most common cause, occurring because 
of incompatibilities between patients and blood donors.8 
Furthermore, routine blood group typing of patients identifies 
ABO and D only.7,8 Typing patients and donors to match for 
the other four common Rh antigens would significantly reduce 
RBC alloimmunization and reduce the frequency of transfusion 
in patients with thalassemia.8,9 Moreover, it is important to 
know the prevalence of Rh phenotypes in the patient population 
receiving regular blood transfusions in order to prevent 
alloimmunization. ABO phenotypes have been observed and 
studied in various regions of the country, but limited data have 
been reported from Pakistan on Rh phenotype prevalence. 
Delineating Rh prevalence is necessary in finding compatible 
blood for patients with Rh alloantibodies requiring regular 
blood transfusion, as emphasized by a regional study done 
on blood donors.9 Therefore, with this objective, this study 
was undertaken to determine the prevalence of ABO and Rh 
phenotypes in patients with transfusion-dependent blood 
disorders.
Materials and Methods
The study was conducted at the blood bank department 
of the National Institute of Blood Diseases and Bone Marrow 
Transplantation, Karachi, Pakistan, from August 2012 to 
October 2014 and was approved by the institutional ethics 
committee. All patients who presented with blood disorders 
requiring frequent blood transfusions during the study period 
and who had not yet received their first transfusion were 
included in the study. Informed consent was obtained in the 
local language before enrolling patients in the study.
A 5.0-mL blood sample was drawn from each patient: 
2.0 mL in a tube containing ethylenediaminetetraacetic acid 
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(EDTA) and 3.0 mL in a plain vial. ABO and Rh were tested 
using the tube method for serologic testing.
Forward and reverse ABO grouping was performed by the 
tube method and by gel technology. For forward ABO grouping, 
commercially available monoclonal blood group antisera 
(anti-A; anti-B; anti-A,B; anti-H; anti-A1) were used, and for 
reverse grouping, 3–5 percent pooled RBC suspensions of 
group A, B, and O cells prepared in-house were used. Gel testing 
by IDcard LISS/Coombs was also used as required. D typing 
was done by the tube method using monoclonal/polyclonal 
anti-D (Rh0 and Rh1) and by using the gel method card. For 
detecting C, c, E, and e, specific monoclonal reagent antisera 
were used and testing was performed using the standard tube 
agglutination method. Samples showing no agglutination with 
anti-D were tested by the indirect antiglobulin test (IAT) for 
the presence of weak D. 
Both Rh control and Coombs control cells were used to 
ensure diagnostic sensitivity and specificity for the detection 
of D. In addition, commercial RBCs (rr, R1R1, and R2R2) were 
used with negative antigenic expression of E, C, c, and e to 
serve as controls for the antisera testing; false-positive and 
false-negative results were avoided by performing quality 
control with each step. 
All antisera, gel cards, and reagent red cells used in the 
ABO and Rh testing were obtained from Diamed (Cressier FR, 
Switzerland).
A statistical package (SPSS-17, IBM, Armonk, NY) 
was used to analyze the data. Prevalence percentages were 
computed for categorical variables, and mean and standard 
deviation (SD) were calculated for quantitative variables.
Results
A total of 242 patients, having known blood disorders 
that required frequent blood transfusions and having no prior 
history of transfusion, were enrolled after obtaining informed 
consent; 146 (60%) were male and 96 (40%) were female. The 
patients included 222 with known cases of beta thalassemia 
major, 12 with aplastic anemia, 4 with pure RBC aplasia, 2 with 
Diamond-Blackfan anemia, and 2 with chronic lymphocytic 
leukemia. Thus, the majority were patients with thalassemia 
major. Their ages ranged from 1 month to 40 years, and their 
median age was 3 years. Prevalence of ABO and D phenotypes 
is shown in Figure 1. The overall prevalence of Rh phenotypes 
is shown in Figure 2. In this group, 232 (96%) were D+ and 
10 (4%) were D–. All of the D– patients were observed to 
be rr; weak D was not found in any of the D– patients. The 
prevalence of Rh antigens in our study and their similarities 
with other Asian populations is shown in Table 1.10,11
Discussion
The prevalence of ABO and D phenotypes among the 
studied patients were as follows: group O, D+ (38.8%), group 
O, D– (2.5%), group B, D+ (32.2%), group A, D+ (17.4%), 
group A, D– (1.7%), and group AB, D+ (7.4%). Analysis from 
previous studies on the prevalence of ABO in the Pakistan 
population revealed that, in the provinces of Sindh and 
Baluchistan, the order of prevalence of ABO phenotypes is 
O > B > A > AB, which is similar to that of the present study; 
whereas in the regions of Punjab and Khyber Pakhtunkhwa, 
the order was B > O > A > AB, with B being the most prevalent 
Fig. 1 Prevalence of ABO and D phenotypes in the studied Pakistan 
patient population.






Fig. 2 Prevalence of Rh phenotypes in the studied Pakistan patient 
population.





Table 1. Comparison of prevalence of Rh antigens in the studied 











e 97 97.3 98.3
D 95 91.1 84.76
C 89.6 73.2 84.76
c 62.8 71 52.82
E 22.6 21 17.9
UAE = United Arab Emirates.
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ABO blood group.12–16 Studies done in the United States, 
Britain, Bangladesh, Sudan, India, and Saudi Arabia6,17–21 also 
revealed that group O is the most prevalent ABO blood group. 
In Nepal, however, group A is the most prevalent ABO group.22 
Group AB is the least prevalent blood group throughout the 
world, and the same was found in our study.18–22
Our results show that none of the patients whose 
samples typed as D– had weak D; Sharma and colleagues in 
India1 observed the same. The most and least prevalent Rh 
antigens in our study population were e (97%) and E (22.6%), 
respectively. This finding is in concordance with other Asian 
studies, as shown in Table 1.10,11 Similar findings were observed 
in Palestine and Europe, where e was the most prevalent and E 
was the least prevalent Rh antigen.6,23 In another Indian study, 
however, among Rh antigens, D was the most prevalent.1 
According to a study done in Sudan, the prevalence of Rh 
antigens was D (93%), e (79.5%), c (68.5%), C, (27%), and E 
(18.5%).3
In our study, R1R1 was found to be the most prevalent Rh 
phenotype, and all of our D– patients were observed to be rr. 
Similar results were observed by Sharma et al.1 In another 
study, R1R1 was also found to be most prevalent.24
In Pakistan, limited studies are available on Rh 
phenotypes. A recent regional study identifying the ABO and 
Rh phenotypes in blood donors showed quite similar results as 
we found in our patients, which shows that the phenotypes of 
frequently transfused patients do not differ from the regional 
donor pool in Pakistan.9 Nonetheless, studies on a larger scale 
are needed for us to identify the actual RBC phenotypes of 
our population. Because antibodies against Rh antigens are 
implicated as the most common cause of alloimmunization 
in patients in Pakistan requiring frequent blood transfusions, 
transfusion of Rh antigen–matched blood, especially in 
this patient population, may significantly reduce the rate of 
alloimmunization.7–9
Once an antibody develops in a patient, the only blood that 
can be transfused to that patient without harm is blood that 
is antigen-negative for the identified antibody. In addition to 
patient Rh typing, donor Rh typing must also be performed. 
Donor typing would help us build an inventory of various 
Rh-phenotyped units that could be matched to a patient’s 
Rh phenotype in addition to providing the required antigen-
negative blood if the patient has non-Rh antibodies. This 
inventory would save time and resources in times of need. The 
lack of information on the Rh phenotypes in our donor pool is 
one of the major limitations of our study.
In conclusion, our study showed the order of prevalence 
of ABO phenotypes in Pakistan patients was O > B > A > AB. 
In the Rh system, e was the most prevalent antigen and the 
least common was E. In Rh phenotypes identified in our study 
population, R1R1 was the most prevalent and rr was the least 
prevalent. Rh antigenic phenotyping, along with antibody 
screening and antibody identification prior to transfusion of 
patients requiring multiple transfusions, should be performed 
on all patients to reduce alloimmunization. Furthermore, 
complete Rh typing of blood donors and regional studies on 
larger donor populations are needed to help not only in finding 
compatible units of blood, but in building a donor database of 
common as well as rare phenotypes.
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